You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.
You are now leaving ironwoodpharma.com.

IW-3718

Completed Phase II Clinical Development

Area of focus:

Uncontrolled Gastroesophageal Reflux Disease (uGERD)
Tens of millions of U.S. adults suffer from GERD.1 Of these, an estimated 10 million patients taking a proton pump inhibitor (PPI) continue to experience symptoms of GERD, such as heartburn and regurgitation.2,3 While PPIs suppress production of stomach acid, research suggests reflux of bile from the intestine into the stomach and esophagus may play a role in the ongoing symptoms of some patients with uGERD.

Our candidate:

IW-3718 is an investigational gastric retentive formulation of a bile acid sequestrant developed by Ironwood. IW-3718 is being investigated to evaluate its safety and efficacy—including its effect on heartburn severity—in patients taking a PPI and continuing to suffer with uGERD. IW-3718 is wholly-owned by Ironwood Pharmaceuticals, and has completed a Phase IIb trial in patients with uGERD.

« Back to Pipeline


1) ElSerag, Hashem, “Update on the epidemiology of gastro-oesophageal reflux disease: A systemic review,” Gut, 2014; 2) Lieberman GI Patients Landscape Survey, 2010; 3) U.S. Census, 2015